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doi:10.1016/j.kjms.2011.06.002Abstract To present single institution open-label experience with intravesical liposomes
(LPs), a mucosal protective agent, in patients with interstitial cystitis/painful bladder
syndrome (IC/PBS) and to assess the safety and efficacy on IC/PBS symptoms. A total of 17
symptomatic IC/PBS patients were treated with intravesical LPs (80 mg/40 mL distilled
water) once a week for 4 weeks (nZ 12) or twice a week treatment for 4 weeks (nZ 5).
The primary outcome was the change in the O’Leary-Sant Symptom/Problem score and
O’Leary-Sant total Score from baseline to Week 4 and Week 8. Other outcome measurements
included the changes in pain scale, urgency scale, voiding log, and patient global assessment.
Both weekly and biweekly LP instillation regiments were well tolerated. The incidence of
urinary incontinence, retention, or unanticipated adverse changes was not noted at any dose
either during the treatment or at the 4-week follow-up. The O’Leary-Sant Symptom/Problem
score, O’Leary-Sant total Score, and pain score were significantly improved from baseline at
both dose regimens with added benefit with the biweekly regimen. Intravesical LPs treat-
ment is safe and its efficacy has sustained duration. Furthermore large-scale, placebo-
controlled studies are warranted to assess the efficacy for this promising new treatment
for IC/PBS.
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Interstitial cystitis/painful bladder syndrome (IC/PBS) is
a clinical diagnosis that relies on symptoms of suprapubic/
bladder discomfort related to bladder filling that is
accompanied by urinary frequency, urgency, or nocturia, ined.
438 W.-C. Lee et al.the absence of infection or another pathological condition
[1,2]. Although the pathogenesis of IC/PBS is complex and
uncertain, a defect in the glycosaminoglycan layer and
dysfunctional urothelial barrier has been proposed [3]. A
dysfunctional epithelium allows the transepithelial migra-
tion of noxious substances in the urine, such as potassium,
which can depolarize subepithelial afferent nerves and
provoke bladder pain and urinary frequency [4].
The principles for treatment of IC/PBS are based on (1)
controlling the dysfunctional epithelium; (2) inhibiting
neurogenic inflammation; (3) suppression of allergies; and
(4) pain control [5]. The current treatment methods used for
IC/PBS include dietary manipulation, oral therapy (pento-
sanpolysulfate, antispasmodics, anti-inflammatories), or
intravesical therapy (dimethyl sulfoxide, heparin-like drugs,
resiniferatoxin, and botulinum toxin) [5e7]. However,
concerns have been raised about their safety, efficacy, and
unfavorable pharmacodynamics. Thus, there is a significant
medical need for additional treatment options for those
suffering from refractory IC/PBS.
Liposomes (LPs) are vesicles or bubbles of phospholipids
filled with water instead of air dispersed in aqueous medium
[8e10]. The propensity of LPs to bind water and adhere as
a molecular film on cell surfaces has made them a favorite
choice for topical drug carriers [8e10]. Studies involving
protamine sulfate-mediated bladder injury demonstrated
the ability of LPs to act as a bladder protective agent [11]. In
addition, anti-inflammatory effect of empty LPs composed
of different bioactive phospholipids has been observed in
various other tissues, including but not limited to skin, eye
membranes, and intestinal tissues [12].
We hypothesized that intravesical administration of LPs
in IC/PBS patients will improve the barrier function and
result in palliation of symptoms. The previously reported
safety and efficacy of LPs compared with oral pento-
sanpolysulfate prompted the present study to expand and
assess the safety and efficacy of LPs at two different dose
regiments in IC/PBS patients [13].Materials and methods
The study was conducted at Chang Gung Memorial Hospital
Kaohsiung, with the approval of the institutional review
board. Informed consent for the procedure was obtained
from all patients. A total of 17 IC/PBS patients were
treated with intravesical LP-08 (Lipella Pharmaceuticals,
Inc., Pittsburgh, PA, USA; 80 mg/40 mL distilled water)
once a week for 4 weeks courses of treatment (nZ 12)
between October 2007 and October 2008 [13], and an
additional 5 patients were assessed after twice a week
instillation for 4 weeks between November 2008 and May
2009.
Patients were selected for enrollment into the study
with a diagnosis of IC/PBS based on a history of symptoms,
including number of voids per day (10 or more), average
voided volume (50e200 mL), nocturia (at least 1), pain
scale (suprapubic or bladder pain, at least 1 on a 0e5 pain
scale), and urgency scale (at least 1 on a 0e5 urgency
scale), for 6 months or longer. In addition, patients had to
have negative urinary cytology studies and cultures, and
cystoscopy to rule out other pathological conditions.Patients were excluded from participation in the study
for age less than 20 years, pregnancy or lactation, bleeding
diathesis, use of anticoagulant therapy, active bleeding
peptic ulcer disease, chronic use of narcotics, obvious
neurological impairment, or known allergy to LPs [13].
LPs instillations were performed in the urology clinic using
an 8 French catheter for LP-08 instillation. Before inserting
the catheter into the urethra, 2% lidocaine hydrochloride
jelly was applied to the catheter tip. Then the bladder was
drained from any postvoid residual and the LPs was instilled
(80 mg LP-08/40 mL distilled water) and retained for
a minimum of 30 minutes to a maximum of 60 minutes and
bladder contents were ultimately voided out [13]. Treatment
outcome measures included the change from baseline to the
end ofWeek 4 andWeek 8 in the severity of IC/PBS symptoms
measured by the O’Leary-Sant IC symptom index (total
scoreZ 20) and O’Leary-Sant IC problem index (total
scoreZ 16) [14]. Higher scores indicate more severe symp-
toms. The pain assessment scale (range: 0e5; 0: no pain, 5:
severe pain), urgency scale (range: 0e5; 0: no urgency, 5:
severe urgency), and voiding diaries thatmeasure the voiding
frequency for a duration of 72 hours were completed at
baseline, Week 4, and Week 8. Global assessment of treat-
ment was categorized into worsened, stationary, mildly
improved, moderately improved, and excellent at Week 4
and Week 8.
For each treatment group, parameters expressed were
mean standard deviation at Week 4 and Week 8 and
compared with their baseline values and between groups
using the Student t test. A p value less than 0.05 was
considered statistically significant.Results
Baseline patient characteristics are presented in Table 1.
All cases were classified as moderate IC/PBS case (LPs once
a week group: 2 of 12; LPs twice a week group: 1 of 5) or
severe IC/PBS cases (LPs once a week group: 10 of 12; LPs
twice a week group: 4 of 5) based on O’Leary-Sant IC
symptom index cut points of 0e6 as mild, 7e13 as
moderate, and 14e20 as severe [13,14].
Primary objective of our study was safety. None of the
patients with LP-08 instillation developed urinary inconti-
nence, retention, or infection. There were no unanticipated
adverse event and no significant worsening of symptoms in
follow-up time period. Two patients in the LPs once a week-
treated group and a single patient in the LPs twice a week-
treated group reported mild discomfort while holding LP for
30e60 minutes in the bladder that disappeared on voiding.
It was most likely because of the IC/PBS characteristic of
bladder pain related to bladder distension. None of the
patient required oral or systemic analgesics with LP-08.
The O’Leary-Sant Symptom/Problem score, O’Leary-Sant
total Score, and pain score showed significantly greater
improvement in the biweekly group than the weekly group
at the Week 4 (63.0% vs. 22.9%, 61.0% vs. 18.6%, 62.0% vs.
20.8%, 57.9% vs. 39.5%; Fig. 1), but there were no significant
difference at Week 8 (Fig. 2) and urgency score.
Significant greater decreases in urinary frequency
(4.4 3.3 and2.5 4.3; 28.2% vs. 14.3%) and increases in
voided volume (36.0.1 41.1 and 7.1 39.9; 28.0% vs. 7.2%)
Table 1 Baseline patient characteristics by treatment group
Baseline characteristics Mean SD
LP1 (once a week, nZ 12) LP2 (twice a week, nZ 5)
Patient age (y) 47.8 11.1 44.2 8.1
O’leary-Sant Symptom Score 15.3 2.5 16.2 2.6
O’leary-Sant Problem Score 14.0 1.9 15.4 0.9
O’leary-Sant total Score 29.3 4.0 31.6 3.4
Pain score (0e5) 3.6 1.5 4.4 0.9
Urgency score (0e5) 4.3 0.9 3.8 1.1
Voiding frequency 17.5 6.0 15.6 3.8
Mean voided volume (mL) 98.4 37.1 128.2 68.0
Nocturia 3.1 1.0 3.1 1.6
Qmax (mL/sec) 11.4 5.3 14.3 3.8
RU (mL) 27.1 27.7 44.3 33.0
There were no statistically significant differences in baseline parameters between the two groups.
LPZ liposome; QmaxZmaximal flow rate; RUZ residual urine; SDZ standard deviation.
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at Week 4 but not at Week 8 (urinary frequency 14.7% vs.
14.9%; voided volume 24.9% vs. 27.5%). There were no
significant differences in the decreases of nocturia (48.4% vs.
32.3% at Week 4 and 41.9% vs. 32.3% at Week 8). There were
no significant differences in the increases of voided volume
(25.0% vs. 27.5% for the biweekly and the weekly group) at
Week 8.
Of the five patients in the biweekly group, 1, 1, and 2 had
a mild, moderate, and excellent response at Week 4 and 1,
2, and 1 had a mild, moderate, and excellent response,
respectively, at Week 8. This was not significantly different
when compared with the results in the 12 patients in the
weekly group, including 3, 2, and 1 had a mild, moderate,
and excellent response at Week 4 and 4, 1, and 2 had a mild,
moderate, and excellent response, respectively, at Week 8.Discussion
The goal of IC/PBS therapy is to reduce the symptoms and
improve the quality of life. With a 4-week of treatment
with LP-08 (80 mg/40 mL distilled water) once a week [13]
or twice a week instilled into the bladder, we demonstratedFigure 1. Treatment parameters at Week 4. The O’Leary-Sant Sym
showed significantly greater improvement in the biweekly group (L
SDZ standard deviation.that 6 of 12 patients (50%) and 4 of 5 patients have
responded to LPs treatment, respectively. The effect was
maintained for 2 months.
The prevailing understanding of IC/PBS considers
disruption of the urothelial barrier as a primary cause.
Disrupted urothelium allows unrestricted access of noxious
substances, such as high concentration of potassium to the
submucosal nerve filaments that may initiate a cascade of
signaling events leading to associated irritative voiding
symptoms and bladder pain. This understanding explains
the moderate efficacy of pentosan polysulfate, which is the
only oral medication approved by the Food and Drug
Administration for IC/PBS. There seem to be a role of
neuroinflammation in the pathology of IC/PBS, which is
supported by the current clinical testing of nerve growth
factor antibody across the world [5,6,15].
The characteristic of LPs to serve as a “lotion” by
adhering to a wounded or leaked bladder mucosa prompted
us to examine the use of intravesical novel LPs as safe and
effective treatment of IC/PBS patients with moderate or
severe symptoms. Our previous study showed that the use
of intravesical LPs once a week for 4 weeks achieved similar
or greater efficacy as oral PPS. The current report sug-
gested that the more frequent treatment (LPs instillationptom/Problem score, O’Leary-Sant total Score, and pain score
P2) than the weekly group (LP1) at the Week 4. LPZ liposome;
Figure 2. Treatment parameters at Week 8. There were no significant difference in treatment parameters between the biweekly
group (LP2) and the weekly group (LP1) at Week 8. LPZ liposome; SDZ standard deviation.
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with acute symptoms and may be preferred for episodes of
IC/PBS flare-up.
The main drawback of the present study was the lack of
placebo control randomization and small sample size. It is
difficult to accumulate large sample size with the investi-
gator-initiated study without multiple center study. Further
studies using a multi-institutional, placebo-controlled trial
to minimize the bias is necessary to elucidate the role of
intravesical LPs in IC/PBS treatment. Previous studies have
shown that apart from transmembrane uroplakin proteins,
the lipids in the apical membrane of the umbrella cells, an
uppermost layer of the urothelium, are also an integral
component of the permeability barrier in the bladder [16].
They seem to play important roles in reducing the perme-
ability of the apical membrane to water, ammonia,
protons, and urea [17]. The therapeutic effect of empty LPs
in the IC/PBS patients supports the notion that the
dysfunctional urothelium of patients with IC/PBS may also
involve deficiency in the lipid structure of the urothelium
apart from glycosaminoglycan layer depletion [18].
In conclusion, intravesical LPs instillation is well tolerated
and effective, and more frequent instillation may improve
efficacy and may be beneficial for symptom flare-up.
However, the follow-up period is not enough and the effects
after 8 weeks are not clear. Further large-scale, placebo-
controlled studies are necessary to evaluate the therapeutic
potential of intravesical LPs for IC/PBS.References
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